Shantha Biotechnics commences commercial productionIllustrative image – not actual.

Shantha Biotechnics, an arm of Sanofi Pasteur, has started commercial production at its new vaccine production facility in the special economic zone of Muppireddipalli, near Hyderabad.

The plant has been set up with an investment of Rs 250 crore and has obtained the regulatory approvals from the World Health Organisation (WHO) and Indian authorities.

The plant will be used initially for the production of its five-in-one vaccine, Shan5, besides the cholera vaccine.

← All latest storiesBack to top →